Infinity Pharmaceuticals
BiotechUSAClosed 2023
Total Raised
Undisclosed
Peak Valuation
Undisclosed
Employees
—
Year Collapsed
2023
Business model
Clinical-stage biopharmaceutical developing cancer drug candidates targeting the tumor microenvironment.
In brief
A nearly two-decade-old cancer drug developer that had negotiated a merger with MEI Pharma expected to bring in $100 million — funding projected to last until 2025 for its three cancer drug candidates. When MEI's own shareholders failed to approve the deal, the rescue funding eva…
See the What Happened tab for the full account.
Key facts
- Founded
- 2001
- Closed
- 2023
- Headquarters
- Cambridge, USA
- Industry
- Biotech
- Employees
- —
- Revenue
- Undisclosed
- Founders
- Julian Adams and others
Related failures
Vedere Bio
2019–2023Biotech · USA
Ran out of funding$77M9 Meters Biopharma
2016–2023Biotech · USA
Ran out of fundingUndisclosedAcorda Therapeutics
1995–2024Biotech · USA
Ran out of fundingUndisclosedAthersys
1995–2024Biotech · USA
Ran out of fundingUndisclosedEiger BioPharmaceuticals
2008–2024Biotech · USA
Ran out of fundingUndisclosedHumanigen
1999–2024Biotech · USA
Ran out of fundingUndisclosed
Often compared with: Bristol Myers Squibb, Merck Oncology.